MILWAUKEE, July 16 (UPI) -- UCB said Monday it has launched in the United States its Neupro transdermal patch for the treatment of early-stage Parkinson's disease.
The company said it would co-promote the once-daily, Neupro rotigotine transdermal system -- which contains a dopamine agonist -- with its subsidiary Schwarz Pharma.
In connection with the rollout of the new Parkinson's treatment, UCB said the partners would also launch a Parkinson's awareness campaign dubbed PD-Aware to increase understanding of the disease as well as its latest therapies.
"Disabling Parkinson's symptoms can be well controlled with available medications, but may return as the effects of Parkinson's disease medications wear off," C. Warren Olanow, professor of neuroscience at the Mount Sinai School of Medicine in New York, said in a statement issued by the company. "Neupro is the first transdermal or patch formulation available for the treatment of Parkinson's disease. It provides continuous drug delivery for 24 hours, throughout the day and night."
UCB said Neupro won U.S. approval in May and was tested in 1,500 Parkinson's patients.
